Discontinued — last reported Q2 '24
Business Segments · Income (loss) from equity method investments
U.S. Pharmaceutical — Income (loss) from equity method investments
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ2 2024
Last reportedQ2 2024
Rolls up toEquity Method Income
How to read this metric
An increase indicates strong performance from strategic partnerships and joint ventures, contributing positively to segment earnings.
Detailed definition
This metric represents the segment's proportional share of the net earnings or losses from entities in which it holds a...
Peer comparison
Standard reporting line for large healthcare conglomerates that utilize joint ventures to expand distribution capabilities or service offerings.
Metric ID:
mck_segment_u_s_pharmaceutical_income_loss_from_equity_method_investmentsHistorical Data
1 periods
| Q2 '24 | |
|---|---|
| Value | -$43.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — income (loss) from equity method investments?
- McKesson (MCK) reported u.s. pharmaceutical — income (loss) from equity method investments of -$43.00M in Q2 2024.
- What does u.s. pharmaceutical — income (loss) from equity method investments mean?
- The segment's share of profits or losses from companies where it holds a minority ownership stake.